

Class	Subclass
ISSUE CLASSIFICATION	

**FILED UNDER 35 U.S.C. 371**

PATENT NUMBER

**ABANDONED**

## U.S. UTILITY Patent Application

O.I.P.E.		PATENT DATE
SCANNED	5-4	Q.A.

APPLICATION NO. 09/889982	CONT/PRIOR D	CLASS 063 435	SUBCLASS 6	ART UNIT <del>2859</del> 1110	EXAMINER (92607) PNK/ELN, GFT
------------------------------	-----------------	---------------------	---------------	-------------------------------------	-------------------------------------

## APPLICANTS

Tariq Rana  
N. Tamilarasu  
Ikramul Haq

**TITLE**

Tat-derived oligonucleotides and its method of production and use in high affinity and specific binding HIV-1 TAR RNA

PTO-2040  
12/89

**BEST AVAILABLE COPY**

<b>ISSUING CLASSIFICATION</b>									
<b>ORIGINAL</b>			<b>CROSS REFERENCE(S)</b>						
<b>CLASS</b>	<b>SUBCLASS</b>		<b>CLASS</b>	<b>SUBCLASS (ONE SUBCLASS PER BLOCK)</b>					
<b>INTERNATIONAL CLASSIFICATION</b>									

☐ Continued on Issue Slip Inside File Jacket

<input type="checkbox"/> <b>TERMINAL DISCLAIMER</b>	<b>DRAWINGS</b>			<b>CLAIMS ALLOWED</b>	
	<b>Sheets Drwg.</b>	<b>Figs. Drwg.</b>	<b>Print Fig..</b>	<b>Total Claims</b>	<b>Print Claim for O.G.</b>
<input type="checkbox"/> The term of this patent subsequent to _____ (date) has been disclaimed.				<b>NOTICE OF ALLOWANCE MAILED</b>	
<input type="checkbox"/> The term of this patent shall not extend beyond the expiration date of U.S Patent. No. _____  _____  _____					
				<b>ISSUE FEE</b>	
				<b>Amount Due</b>	<b>Date Paid</b>
<input type="checkbox"/> The terminal ____months of this patent have been disclaimed.				<b>ISSUE BATCH NUMBER</b>	

**WARNING:**

**WARNING:** The information disclosed herein may be restricted. Unauthorized disclosure may be prohibited by the United States Code Title 35, Sections 122, 181 and 368. Possession outside the U.S. Patent & Trademark Office is restricted to authorized employees and contractors only.

Form PTO-436A  
(Rev. 6/99)

FILED WITH: ☐ DISK (CRF) ☐ FICHE ☐ CD-ROM  
(Attached in pocket on right inside flap)

(FACE)